Can a patient take Humilin (Regular Insulin), Glargine (Insulin Glargine) and Humalog (Insulin Lispro) together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a Patient Take Humulin (Regular Insulin), Glargine (Insulin Glargine), and Humalog (Insulin Lispro) Together?

Yes, a patient can safely take Humulin (regular insulin), insulin glargine, and Humalog (insulin lispro) together as separate injections, but they must NOT be mixed in the same syringe, particularly glargine which cannot be mixed with any other insulin. 1

Critical Administration Rules

Insulin Glargine Cannot Be Mixed

  • Insulin glargine must be administered as a separate injection and should never be mixed with other forms of insulin due to the low pH of its diluent. 1
  • The acidic pH of glargine's formulation causes precipitation when mixed with other insulins, altering the pharmacokinetic properties and potentially causing unpredictable glucose control. 1
  • No other medication or diluent should be mixed with any insulin product unless approved by the prescribing physician. 1

Rapid-Acting and Regular Insulin Can Be Mixed

  • Rapid-acting insulin (Humalog/lispro) can be mixed with NPH, lente, and ultralente insulins if needed. 1
  • When rapid-acting insulin is mixed with intermediate-acting insulin, the mixture should be injected within 15 minutes before a meal. 1
  • However, there is typically no clinical need to mix regular insulin (Humulin) with rapid-acting insulin (Humalog) since they serve similar purposes with different onset times. 1

Practical Regimen Structure

Typical Use Pattern

  • Insulin glargine provides basal (background) insulin coverage over 24 hours with a peakless profile, administered once daily at a consistent time. 1, 2, 3
  • Humalog (rapid-acting lispro) covers mealtime glucose spikes, administered 5-15 minutes before meals with onset in 5 minutes and duration of 3-4 hours. 1, 4
  • Humulin (regular insulin) has a slower onset (15 minutes), peaks at 3-4 hours, and lasts 6-8 hours, typically given 30 minutes before meals. 1

Why Use Both Rapid and Regular Insulin?

  • In most modern regimens, patients use either rapid-acting (Humalog) OR regular insulin (Humulin) for mealtime coverage, not both simultaneously. 4
  • Using both rapid-acting and regular insulin together increases complexity and hypoglycemia risk without clear benefit in most cases. 1, 4
  • If a patient is currently on this regimen and well-controlled, they should maintain their standard procedure. 1

Administration Technique

Separate Injections Required

  • Each insulin type must be administered as a separate injection when glargine is part of the regimen. 1
  • Rotate injection sites to prevent lipodystrophy and ensure consistent absorption. 1
  • Insulin glargine should be given at the same time each day for optimal efficacy. 2

Timing Considerations

  • Glargine: Once daily at a consistent time (morning or evening based on patient preference and glucose patterns). 2, 3
  • Humalog: 5-15 minutes before meals. 1, 4
  • Humulin (regular): 30 minutes before meals. 1

Common Pitfalls to Avoid

Critical Errors

  • Never mix insulin glargine with any other insulin in the same syringe—this is the most important safety consideration. 1
  • Do not assume all insulins can be mixed; only specific combinations are safe (NPH with rapid-acting or regular insulin). 1
  • Avoid using both rapid-acting and regular insulin for the same meal unless specifically prescribed and monitored, as this significantly increases hypoglycemia risk. 1

Monitoring Requirements

  • Patients on multiple insulin types require frequent blood glucose monitoring to adjust doses appropriately. 2
  • Watch for hypoglycemia, particularly overnight with glargine, though it has lower risk than NPH insulin. 1, 3, 5
  • If basal insulin dose exceeds 0.5 units/kg/day and A1C remains above target, consider advancing to combination injectable therapy with GLP-1 receptor agonists rather than adding more insulin types. 2, 6

Reassess the Regimen

  • Question whether using three different insulin types is truly necessary—most patients achieve excellent control with basal insulin (glargine) plus one mealtime insulin (either Humalog OR Humulin, not both). 1, 4
  • The combination of regular and rapid-acting insulin for mealtime coverage adds complexity without clear evidence of superiority over using rapid-acting insulin alone. 4
  • Patients who are well controlled on their current mixed-insulin regimen should maintain their standard procedure for preparing insulin doses. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Insulin Glargine Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Insulin Glargine: a review 8 years after its introduction.

Expert opinion on pharmacotherapy, 2009

Research

Insulin analog therapy: improving the match with physiologic insulin secretion.

The Journal of the American Osteopathic Association, 2009

Research

Insulin glargine (Lantus).

International journal of clinical practice, 2002

Guideline

Optimizing Insulin Regimens

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.